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Proper regulation of receptor tyrosine kinase (RTK)–Ras–mitogen-activated protein kinase (MAPK) sig-
naling pathways is critical for normal development and the prevention of cancer. SOS is a dual-function
guanine nucleotide exchange factor (GEF) that catalyzes exchange on Ras and Rac. Although the physiologic
role of SOS and its CDC25 domain in RTK-mediated Ras activation is well established, the in vivo function of
its Dbl Rac GEF domain is less clear. We have identified a novel gain-of-function missense mutation in the Dbl
domain of Caenorhabditis elegans SOS-1 that promotes epidermal growth factor receptor (EGFR) signaling in
vivo. Our data indicate that a major developmental function of the Dbl domain is to inhibit EGF-dependent
MAPK activation. The amount of inhibition conferred by the Dbl domain is equal to that of established
trans-acting inhibitors of the EGFR pathway, including c-Cbl and RasGAP, and more than that of MAPK
phosphatase. In conjunction with molecular modeling, our data suggest that the C. elegans mutation, as well
as an equivalent mutation in human SOS1, activates the MAPK pathway by disrupting an autoinhibitory
function of the Dbl domain on Ras activation. Our work suggests that functionally similar point mutations in
humans could directly contribute to disease.
Receptor tyrosine kinase (RTK)–Ras–mitogen-activated
protein kinase (MAPK) signaling pathways play profound
roles in development and, when improperly regulated, can
contribute to oncogenesis (8). Although most of the core com-
ponents of RTK-Ras-MAPK pathways were discovered a de-
cade ago, the diverse mechanisms for positive and negative
regulation are still being elucidated. Genetic model organisms,
such as Caenorhabditis elegans and Drosophila melanogaster,
have been invaluable for the study of the regulation of these
pathways. In the C. elegans hermaphrodite, a single epidermal
growth factor (EGF)-like ligand and a single EGF receptor
(EGFR) family member are required for normal development
and behavior (61). A canonical EGFR-Grb2-SOS-Ras-Raf-
Mek-MAPK pathway is essential for viability past the first
larval stage and for development of the vulva, while an EGF-
dependent inositol (1,4,5)-trisphosphate (IP3) pathway that is
Ras independent controls ovulation behavior. The vulva devel-
ops through the induction of vulval cell fates in three out of six
progenitor cells. The initiating events are the production of
LIN-3 (EGF) from the anchor cell in the somatic gonad and its
stimulation of LET-23 (EGFR) on the underlying P6.p pro-
genitor cell. In the presence of sufficient levels of EGFR sig-
naling and a cooperating signal from a Wnt pathway, Notch
receptor ligands are upregulated and stimulate LIN-12 (Notch)
on the adjacent P5.p and P7.p progenitors (17). Ultimately,
eight progeny are produced from P6.p and seven each from
P5.p and P7.p to form a mature 22-cell vulva. The remaining
progenitor cells, P3.p, P4.p, and P8.p, fuse with an underlying
hypodermal syncytium and do not adopt vulval fates.
Vulval development is well suited for studying EGFR-Ras-
MAPK pathway regulation, since small deviations in signaling
intensity quantifiably affect vulval development. Too little sig-
naling results in fewer than three progenitor cells adopting
vulval fates (vulvaless [Vul]), while excessive signaling results
in more than three progenitor cells adopting vulval fates (mul-
tivulva [Muv]). Using various genetically defined sensitized
backgrounds of either too little or too much signaling, a variety
of mechanisms have been identified that regulate output or
responsiveness to EGFR-Ras-MAPK signaling (61). These
mechanisms include cell-autonomous trans-acting factors, such
as SLI-1 (c-Cbl) (45, 96), KSR-1 (54, 87), and GAP-1 (Ras
GAP) (37); cell-autonomous intramolecular constraints, such
as autoinhibitory determinants within the EGFR (50, 62); and
non-cell-autonomous pathways involving heterologous signals
from surrounding neurons and muscles (60).
Here, we describe the isolation of a novel gain-of-function
mutation in the guanine nucleotide exchange factor (GEF)
SOS-1. SOS is a multidomain protein (see Fig. 2B) that in vitro
catalyzes exchange on Ras through its CDC25 domain (16, 28)
and exchange on Rac through its Dbl domain (65). In Dro-
sophila (9, 75), C. elegans (15), and mouse (69, 92), SOS is
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essential for development. Whereas it is clear that SOS and its
CDC25 domain are crucial for RTK-mediated Ras signaling
(9, 15, 69, 75, 92) and that perturbation of this function leads
to developmental defects (9, 15, 75), it is less clear to what
extent its Dbl domain is also required for normal development.
Recent studies have demonstrated that a variety of signals,
including phosphatidylinositides (65), protein phosphorylation
(82), and protein interactions (80), can regulate SOS Rac GEF
activity, suggesting the catalytic activity of the Dbl domain may
also be important for development. We found that our gain-
of-function mutation in sos-1, which strongly affects an EGFR-
Ras-MAPK pathway, lies in the Dbl domain rather than the
CDC25 domain. Genetic analysis indicated that the activated
mutant SOS-1 predominantly signals through Ras, rather than
Rac, suggesting that the Dbl domain has an inhibitory function
in Ras signaling that is separate from its catalytic activity on
Rac proteins. Molecular modeling further suggested that our
mutation may disrupt a recently described in vitro autoinhibi-
tory function of the Dbl domain on CDC25 Ras GEF activity
(84). We also found that human SOS1 (hSOS1) can be acti-
vated by an equivalent mutation. Together, our data demon-
strate a crucial role of the Dbl domain in inhibiting EGFR
pathway activity in vivo and suggest that analogous mutations
in hSOS1 may contribute to disease.
MATERIALS AND METHODS
Strains. C. elegans was cultured at 20°C (13) unless otherwise indicated. The
alleles used were let-23(sy1) and let-23(sy16) (2) and rol-6(e187) (21) on LGII;
pha-1(e2123ts) (34) on LGIII; ced-10(n1993) (29), lip-1(zh15) (7), lin-45(sy96)
(41), unc-24(e138) (72), lin-3(n378) (30), let-60(n1876) (5), let-60(sy95) (40, 42),
let-60(n1531) (5), let-60(sy101) (40, 42), let-60(n1046) (5, 30), dpy-20(e1282) (43),
unc-22(s7) (59), and rac-2(ok326) on LGIV; let-341/sos-1(s1031) (44) and unc-
46(e177) (13) on LGV; and sli-1(sy143) (45), gap-1(n1691) (37), unc-2(e55) (13),
and mig-2(mu28) (98) on LGX.
Isolation, mapping, and molecular identification of the sy262 mutation. To
identify new recessive alleles of the sli-1 locus, an F1 noncomplementation screen
was performed. let-23(sy1) males were mutagenized with ethanemethylsulfonate
(13) and crossed into marked let-23(sy1); sli-1(sy143) hermaphrodites. The sy262
mutation was discovered as a dominant let-23(sy1) suppressor that was unlinked
to the sli-1 locus. Standard genetic approaches assigned linkage to chromosome
V. Mapping relative to let-341 (now known to be sos-1) and unc-46 was carried
out by crossing let-23(sy1); sy262 males into heterozygous sos-1(s1031) unc-
46(e177) hermaphrodites. From let-23(sy1)/; sos-1 unc-46/sy262 heterozygotes,
12 Unc non-Let recombinants were picked. After homozygosing let-23(sy1) and
the recombinant chromosome, it was determined that 12/12 recombinants picked
up sy262, indicating sy262 is to the left of unc-46 and close to or to the left of
sos-1. Single-nucleotide polymorphism (SNP) mapping (94) was performed by
crossing CB4856 Hawaiian C. elegans males into hermaphrodites derived from
Bristol, England, carrying let-23(sy1) and the linked sy262 and unc-46 mutations.
After homozygosing the let-23 mutation, Unc non-sy262 recombinants were
picked. Five out of nine recombinants did not pick up the Hawaiian SNP located
at position 9725 of cosmid F41F3, indicating that sy262 is to the left of cosmid
F41F3. However, all of the recombinants picked up the SNP in yeast artificial
chromosome (YAC) Y61A9LA, which is next to the sos-1 gene. Since we did not
find recombinants that crossed over between sy262 and the SNP in Y61A9LA, we
speculated that sy262 must be close to the sos-1 locus. Based on these mapping
data and our genetic data showing that sy262 suppresses a dominant-negative
Ras mutation, but not a Raf reduction-of-function [(rf)] mutation, we speculated
that sy262 was a gain-of-function mutation in sos-1. The entire coding regions of
the sos-1 cDNAs derived from either wild-type or sy262 mutant worms were
sequenced. A single G-to-A transition mutation was found in the sy262 sos-1
cDNA, changing codon 322 from GGA to AGA. The presence of this mutation
in sy262 genomic DNA was confirmed by PCR amplifying and sequencing exon
6 from wild-type and sy262 mutant worms.
Vulval induction and gonad ablations. Vulval development was scored during
the L4 stage under Nomarski optics (86). The number of vulval nuclei was used
to extrapolate how many of the vulval progenitor cells (VPCs) were induced to
adopt vulval fates. A VPC that gave rise to seven or eight great-granddaughters
and no hyp7 tissue was scored as 1.0 cell induction. A VPC in which one daughter
fused with hyp7 and the other daughter divided to generate three or four
great-granddaughter cells was scored as 0.5 cell induction. In wild-type animals,
P5.p, P6.p, and P7.p each undergo 1.0 cell induction, whereas the other Pn.p cells
do not adopt vulval fates, resulting in a total of 3.0 cell inductions. Animals
displaying more than 3.0 cell inductions are Muv, and animals with less than 3.0
cell inductions are Vul. Gonad cells (Z1, Z2, Z3, and Z4) were ablated with a
laser microbeam during the L1 stage (4).
RNAi. Escherichia coli HT115 bacteria containing the respective RNA inter-
ference (RNAi) clones were obtained from the Ahringer bacterial feeding library
(48). The bacteria were grown overnight in LB with 50 g/ml ampicillin and then
spotted onto NG plates containing 1 mM IPTG (isopropyl--D-thiogalacto-
pyranoside) and 50 g/ml ampicillin to make RNAi plates. The next day, Po L4
stage worms were seeded onto the plates. After 2 days, the Po worms were
transferred to fresh RNAi plates, and progeny were scored 4 to 7 days later.
Plasmid constructions. A 4,002-bp cDNA encoding isoform 1 of hSOS1
(GenBank accession number L13857) was used in all experiments. A C-termi-
nally FLAG-tagged expression construct was generated by first cloning an N-
terminal BamHI/KpnI fragment spanning nucleotides 1 to 3146 into the BglII/
KpnI sites of p3XFLAG-CMV-14 (Sigma). A C-terminal fragment spanning
nucleotides 3146 to 4000 that replaced the stop codon with an XbaI site was
generated by PCR using oligonucleotides hSOS1-1 (5-AAC TTG AAT CCG
ATG GGA AAT AGC-3) and hSOS1-2 (5-CTA GCC TAG TCT AGA GGA
AGA ATG GGC ATT CTC CAA CAG-3). This fragment was then ligated to
the N-terminal hSOS1 fragment in the FLAG vector via KpnI/XbaI digestion.
Site-directed mutagenesis using oligonucleotides hSOS1-3 (5-C CAT CCA CTA
GTA GGA AGC CGC TTT GAA GAC TTA GCA GAG-3), hSOS1-4 (5-CTC
TGC TAA GTC TTC AAA GCG GCT TCC TAC TAG TGG ATG G-3), and
Accuprime Pfx DNA Polymerase (Invitrogen) was performed on an XhoI hSOS1
subfragment spanning nucleotides 112 to 896 that had been cloned into pBlue-
script (Stratagene). The mutagenesis changed codon 282 from TGC (Cys) to
CGC (Arg). The mutagenized fragment was then used to replace the correspond-
ing region in the wild-type FLAG-tagged construct via XhoI digestion. All
constructs were verified by sequencing them.
Transient transfections, growth factor stimulations, and Western blotting.
NIH 3T3 and HEK 293 EBNA cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum, penicillin, strep-
tomycin, and glutamine and maintained in a 5% CO2 incubator. The NIH 3T3
cells were plated at 5  105 cells/60-mm dish 12 to 24 h prior to transfection. For
NIH 3T3 cell transfection, 25 l of Lipofectamine (Invitrogen) was combined
with 300 l DMEM and 8 g total DNA and incubated for 30 min at room
temperature. Complexes were added to the cells in the presence of 2.4 ml
DMEM for 5 hours. The transfected cells were washed once with DMEM or
phosphate-buffered saline (PBS) and then starved for an additional 15 to 20 h in
serum-free DMEM. HEK 293 EBNA cells were plated at 1.2  106 cells/60-mm
dish 12 to 24 h prior to transfection. For HEK 293 EBNA cell transfection, 30 l
polyethylenimine (1 mg/ml) was combined with 1.5 ml DMEM and 6.5 g total
DNA and incubated for 15 to 30 min at room temperature. Complexes were
added to the cells in a total of 4 ml of DMEM and incubated for 16 h at 37°C.
The cells were recovered in complete medium for 8 hours before being starved
in serum-free DMEM for 18 to 24 h.
Transfected cells were stimulated with 10 ng/ml human EGF (BD Biosciences)
and lysed in NP-40 lysis buffer (1% Nonidet P40, 150 mM NaCl, 50 mM Tris-Cl
[pH 8.0]) containing 1 g/ml antipain, 1 g/ml aprotinin, 10 g/ml leupeptin, 1
g/ml pepstatin A, 20 g/ml phenylmethylsulfonyl fluoride, 20 mM NaF, 2 mM
sodium orthovanadate, and 20 mM beta-glycerophosphate. Protein concentra-
tions were determined by the bicinchoninic acid assay (Pierce).
Following sodium dodecyl sulfate-polyacrylamide gel electrophoresis, proteins
were transferred to Immobilon-P membranes (Millipore) in transfer buffer (50
mM Tris-base, 40 mM glycine, 0.04% sodium dodecyl sulfate, 10% methanol)
using a semidry transfer apparatus (Owl). The blots were blocked in 5% nonfat
dry milk-TBST (50 mM Tris-Cl, 150 mM NaCl, 0.05% Tween-20 [pH 8.0]) and
probed with anti-phospho-p44/42 MAPK (Cell Signaling, no. 9101; 1:1,000),
anti-FLAG (Sigma, no. F1804; 1:2,000), or anti-p44/42 MAPK (Cell Signaling,
no. 9102; 1:2,000). The blots were developed using ECL Plus (Amersham), and
the intensities of the bands were determined by densitometric scanning, followed
by quantification using ImageJ software (NIH).
SWISS-MODEL. The three-dimensional structure of the C. elegans SOS-1
Dbl-PH-REM-CDC25 domains was modeled using the crystal structure of the
Dbl-PH-REM-CDC25 domains of hSOS1 (crystal structure coordinates
1xd4A.pdb) and the optimize mode of SWISS-MODEL (36, 67, 79), an
Internet-based automated comparative protein-modeling server (http://www
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.expasy.ch/swissmod/SWISS-MODEL.html). In the optimize mode, the SOS
-1 protein sequence was aligned with that of hSOS1 using BLAST (http://www
.ncbi.nlm.nih.gov/BLAST/).
RESULTS
The sy262 mutation acts at the level of Ras and upstream of
Raf. The sy262 mutation was discovered in a sli-1 (c-Cbl) F1
noncomplementation screen (see Materials and Methods) as a
novel mutation that was unlinked to the sli-1 locus but could
still strongly suppress a let-23 (EGFR) reduction-of-function
mutation (Fig. 1 and Table 1). To determine how the sy262
mutation interacts with the EGFR pathway, we performed a
genetic epistasis analysis using standard reduction-of-function
mutations in the EGFR-Ras-MAPK pathway (Fig. 1 and Table
1). By itself, the sy262 mutation does not alter vulval develop-
ment. However, the sy262 mutation strongly suppresses a re-
duction-of-function mutation in lin-3 (EGF), which likely af-
fects EGF processing, and a mutation in let-23 (EGFR), which
affects EGFR localization (47, 56). The sy262 mutation also
suppresses a weak dominant-negative S89F mutation in let-60
(Ras) but does not suppress stronger let-60 (Ras) dominant-
negative mutations (G10R and G15D) or a relatively weak
reduction-of-function mutation in lin-45 (Raf) (40–42). These
data suggest that the sy262 locus normally acts upstream of Raf
and possibly on Ras.
The sy262 mutation maps to the Dbl domain of the Ras/Rac
GEF SOS-1. We used three-factor mapping to place sy262 to
the left of unc-46 and close to or to the left of let-341 (now
known to be sos-1) (see Materials and Methods) on chromo-
some V. We then used SNPs to determine that sy262 was to the
left of cosmid F41F3 and close to the YAC Y61A9LA, which
includes the sos-1 locus (Fig. 2A). There are 22 predicted genes
between the SNP in F41F3 and sos-1. Given our genetic
FIG. 1. The sy262 mutation suppresses the Vul phenotype of a reduc-
tion-of-function mutation in let-23 (EGFR). The animals were photo-
graphed during the mid-L4 larval stage using Nomarski optics. (A) Wild
type. (B) Homozygous sy262 mutant. (C) Homozygous let-23(sy1) reduc-
tion-of-function mutant. (D) Homozygous let-23(sy1); sy262 double mu-
tant. Scale bars  20 m. On the right, the names of the C. elegans and
human (in parentheses) components of the EGFR pathway are indicated.
TABLE 1. The sy262 mutation acts at the level of Ras and upstream of Raf
Genotypea Vulvalinductionb % Muv
c % Vuld ne P valuef
Wild type 3.00 0 0 24
sy262 3.00 0 0 20
lin-3(rf) 1.40 0 95 21
lin-3(rf); sy262 2.93 0 10 20 0.00001 to lin-3(rf)
let-23(rf) 0.23 0 100 20
let-23(rf); sy262 3.80 68 0 22 0.00001 to let-23(rf)
let-23(rf); sy262/ 2.95 35 20 20 0.00001 to let-23(rf)
let-60(S89Fdn)/ 1.55 0 81 21
let-60(S89Fdn)/; sy262 2.80 0 18 22 0.0001 to let-60(S89Fdn)/
let-60(G10Rdn)/ 0.25 0 100 20
let-60(G10Rdn)/; sy262 0.40 0 100 20 0.42 to let-60(G10Rdn)/
let-60(G15Ddn)/ 0.08 0 100 20
let-60(G15Ddn)/; sy262 0.04 0 100 27 0.64 to let-60(G15Ddn)/
lin-45(rf) 2.10 0 70 20
lin-45(rf); sy262 2.14 0 67 21 0.88 to lin-45(rf)
a The complete genotypes are as follows: (i) sy262 sy262 him-5(e1490), (ii) lin-3(rf) lin-3(n378); unc-46(e177), (iii) lin-3(rf); sy262 lin-3(n378); sy262 unc-46(e177), (iv)
let-23(rf) let-23(sy1), (v) let-23(rf); sy262 let-23(sy1); sy262 him-5(e1490), (vi) let-23(rf); sy262/ let-23(sy1); sy262 unc-46(e177)/, (vii) let-60(S89Fdn)/ unc-24(e138)
let-60(sy95)/dpy-20(e1282), (viii) let-60(S89Fdn)/; sy262 unc-24(e138) let-60(sy95)/dpy-20(e1282); sy262 unc-46(e177), (ix) let-60(G10Rdn)/ let-60(sy101) dpy-20(e1282)/
unc-24(e138) unc-22(s7); unc-46(e177), (x) let-60(G10Rdn)/; sy262  let-60(sy101) dpy-20(e1282)/unc-24(e138) unc-22(s7); sy262 unc-46(e177), (xi) let-60(G15Ddn)/ 
let-60(n1531) unc-22(s7)/dpy-20(e1282); unc-46(e177), (xii) let-60(G15Ddn)/; sy262  let-60(n1531) unc-22(s7)/dpy-20(e1282); sy262 unc-46(e177), (xiii) lin-45(rf)  unc-
24(e138) lin-45(sy96), and (xiv) lin-45(rf); sy262  unc-24(e138) lin-45(sy96); sy262 unc-46(e177).
b Average number of vulval progenitor cells adopting vulval fates. Wild type is three. The maximum is six.
c The percentage of animals that have more than three vulval progenitor cells adopting vulval fates.
d The percentage of animals that have fewer than three vulval progenitor cells adopting vulval fates.
e n, number of animals examined.
f Statistical significance of the vulval induction value as determined by a two-tailed Student’s t test.
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epistasis results showing that sy262 acts at the level of Ras and
upstream of Raf, we hypothesized that the sy262 mutation was
a gain-of-function mutation in sos-1. After sequencing the en-
tire coding region of the sos-1 cDNA derived from sy262 mu-
tant animals, we found a single G-to-A mutation in codon 322
that results in a substitution of Arg for Gly in the Dbl domain
(Fig. 2B). The presence of the mutation was also confirmed in
sy262 genomic DNA.
The sy262 (G322R) mutation predominantly affects Ras sig-
naling. SOS-1 and its Drosophila and mammalian orthologs are
multidomain proteins best characterized for their critical bio-
logical roles as Ras GEFs (Fig. 2B) (9, 15, 16, 28, 69, 92).
However, in addition to containing a CDC25 Ras GEF do-
main, SOS-1 also possesses a Dbl domain, which allows the
mammalian protein to function as a Rac GEF (65). The loca-
tion of the sy262 mutation in the Dbl domain suggests at least
two models for the way in which the change may create a
gain-of-function protein. In one model, the sy262 mutation
may relieve one of several previously described forms of inhi-
bition on SOS Rac GEF activity (23, 65, 80–83). For example,
the sy262 mutation might disrupt autoinhibition by the PH
domain on the Rac GEF activity of the Dbl domain (23, 65,
83). In this model, elevated Rac signaling might bypass some of
the requirement for Ras signaling during vulval development.
In the second model, the sy262 mutation might relieve inhibi-
tion of Ras GEF activity. The second model is particularly
appealing, since recent X-ray crystallographic studies of
hSOS1 have uncovered an autoinhibitory function of the Dbl
domain on CDC25 Ras GEF activity (84).
To distinguish between these models, we examined the sen-
sitivity of sy262 mutant SOS-1 to further mutations in either
Ras or Rac (Table 2). For these experiments, we used a back-
ground in which the sy262 mutation suppressed a reduction-
of-function mutation in let-23 (EGFR). When we additionally
lowered Ras levels through a heterozygous strong reduction-
of-function mutation in let-60 (Ras), sy262 activity was strongly
reduced to only 29% of that seen in the presence of two copies
of wild-type Ras. Thus, the activity of SOS-1 G322R is critically
dependent on the amount of Ras. This observation is also
consistent with the failure of sy262 to suppress strong domi-
FIG. 2. The sy262 mutation maps to the Dbl domain of SOS-1.
(A) SNP mapping of sy262. Five out of nine Unc non-sy262 recombi-
nants did not pick up the SNP located at position 9725 of cosmid
F41F3, indicating that sy262 is to the left of cosmid F41F3. All the
recombinants picked up the SNP at 14897 in the YAC Y61A9LA,
which is next to the sos-1 gene. Thus, the sy262 mutation is close to
the sos-1 locus. (B) Architecture of the C. elegans SOS-1 protein
(GenBank accession number AF251308) and location of the sy262
mutation. The numbers refer to amino acid positions. Domain bound-
aries were determined by SMART (http://smart.embl-heidelberg.de/),
except for the REM domain, whose position was determined by a
BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) alignment with hSOS1.
TABLE 2. The sy262 mutation predominantly acts through Ras rather than Rac
Genotypea Vulval inductionb % Muvc % Vuld ne P valuef
Wild type 3.00 0 0 24
sy262 3.00 0 0 20
let-23(rf) 0.23 0 100 20
let-23(rf); sy262 3.80 68 0 22
let-60(rf)/ 3.00 0 0 20
let-23(rf); let-60(rf)/; sy262 1.25 0 80 22 0.00001 to let-23(rf); sy262
rac-2(null) 3.00 0 0 20
let-23(rf); rac-2(null); sy262 3.65 60 0 20 0.50 to let-23(rf); sy262
ced-10(rf) 3.00 0 0 20
let-23(rf); ced-10(rf); sy262 3.90 70 5 20 0.68 to let-23(rf); sy262
mig-2(null) 3.00 0 0 20
let-23(rf); sy262; mig-2(null) 2.85 25 25 20 0.002 to let-23(rf); sy262
let-23(rf); rac-2(RNAi); sy262; mig-2(null) 2.83 30 30 18 0.97 to let-23(rf); sy262; mig-2(null)
let-23(rf); ced-10(RNAi); sy262; mig-2(null) 2.55 21 47 19 0.45 to let-23(rf); sy262; mig-2(null)
let-23(rf); ced10(RNAi); rac-2(RNAi); sy262; mig-2(null) 2.68 30 40 20 0.64 to let-23(rf); sy262; mig-2(null)
a let-23(rf)  let-23(sy1), let-60(rf)/  let-60(n1876) unc-22(s7)/dpy-20(e1282), rac-2(null)  rac-2(ok326), ced-10(rf)  ced-10(n1993), and mig-2(null)  mig-
2(mu28). In the mig-2(null) strains, sy262 was linked to unc-46(e177). In all other strains, sy262 was linked to him-5(e1490). By themselves, the unc-46 and him-5
mutations do not affect vulval development in let-23(rf) animals.
b Average number of vulval progenitor cells adopting vulval fates. Wild type is three. The maximum is six.
c The percentage of animals that have more than three vulval progenitor cells adopting vulval fates.
d The percentage of animals that have fewer than three vulval progenitor cells adopting vulval fates.
e n, number of animals examined.
f Statistical significance of the vulval induction value as determined by a two-tailed Student’s t test.
3698 MODZELEWSKA ET AL. MOL. CELL. BIOL.
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on July 28, 2007 
m
cb.asm
.org
D
ow
nloaded from
 
nant-negative mutations in Ras (Table 1). C. elegans has three
Rac genes: rac-2 (57), ced-10 (71), and mig-2 (98). Although
nonnull mutations in let-60 (Ras) by themselves can reduce
vulval induction (5, 40) (Table 1), single null mutations in
either rac-2 or mig-2 or a single strong reduction-of-function
mutation in ced-10 has no effect on vulval development (Table
2). Thus, unlike the requirement for Ras, vulval development
is not normally dependent on any single Rac gene. Further-
more, in the sensitized background of sy262 suppression of the
let-23 (EGFR) reduction-of-function mutation, rac-2 and
ced-10 mutations still have no effect on vulval development.
However, a null mutation in mig-2 partially reduced sy262-
suppressing activity to 73% of that seen in the presence of
MIG-2. The effect of the mig-2 mutation was not enhanced by
additional reduction of rac-2 and ced-10 through RNAi. Given
that a partial reduction of Ras levels, which by itself is not even
sufficient to weaken Ras activity in its known biological path-
ways (viability, vulval development, and fertility), has a more
profound effect on sy262 activity than null mutations and re-
ductions in function of the three Rac genes (1.25 cells induced
versus 2.68 cells induced, respectively), it is likely that SOS-1
G322R exerts most of its effect through the Ras pathway (see
Discussion).
The Dbl domain mutation increases the sensitivity of the
Ras pathway to upstream signaling. Although a precise mech-
anism has not yet been defined, it has been suggested that SOS
catalytic activity toward the Ras-MAPK pathway might be pos-
itively regulated by growth factor signaling (14, 70). To deter-
mine if the G322R change increases SOS-1 basal activity and
converts it into a constitutively active GEF, we examined
whether the gain-of-function phenotype was still manifested in
the complete absence of upstream signaling from EGF and the
EGFR. We first tested whether the sy262 mutation could still
suppress the Vul phenotype of a let-23 (EGFR) reduction-of-
function mutation in the absence of the EGF-producing an-
chor cell. In wild-type animals, laser ablation of the gonadal
primordium, which gives rise to the anchor cell prior to the
onset of vulval induction, results in 100% of the animals having
absolutely no vulval induction (Table 3). Although a control
G13E gain-of-function change in let-60 (Ras) was still able to
promote some vulval induction in this background, the SOS-1
G322R could not promote vulval development in the complete
absence of EGF (Table 3). Thus, in this assay, SOS-1 G322R
does not appear to be constitutively active.
In another assay, we examined the ability of the sy262 mu-
tation to suppress the lethality conferred by a homozygous
let-23 (EGFR) null mutation. Due to the 100% penetrant
lethality of this mutation, we initially constructed a strain in
which the sy262 mutation was homozygous but the let-23
(EGFR) null mutation was maintained in a heterozygous state.
The let-23 (EGFR) null mutation was linked to a recessive
mutation in the rol-6 gene. Thus, in the absence of suppression,
25% of the progeny die as L1 larvae, and adult rolling animals
are never seen. If there is 100% suppression of let-23(null)
lethality, 25% of the progeny will appear as adult rolling ani-
mals, since this is the expected Mendelian frequency of ho-
mozygosing the mutant let-23 (EGFR) chromosome from het-
erozygous animals. In the presence of a homozygous let-60
(Ras) G13E gain-of-function mutation, 26% of the progeny
were adult rollers (Table 4). This frequency indicates that the
Ras mutation can suppress 100% of the lethality associated
with complete loss of the EGFR. These rollers were 100%
sterile, since an EGF-dependent IP3 pathway, rather than Ras,
is required for hermaphrodite fertility (19). The Ras mutation
was also able to drive excessive vulval induction. Almost 100%
of the animals had all six progenitor cells adopting vulval fates,
rather than the normal three. In contrast to the gain-of-func-
tion Ras mutation, the sy262 mutation resulted in only 1.5% of
total progeny from heterozygous mothers appearing as adult
rollers (Table 4). This translates into a rescue frequency of
only 6%, compared to a rescue frequency of 100% for the
G13E Ras mutation. The rescued sy262 mutant animals were
not rare recombinants, since all were sterile, and on average,
only one progenitor cell was induced to adopt a vulval fate.
Failure of the sy262 mutation to rescue the sterility defect of
let-23 (EGFR) null animals also provides further evidence that
the Ras effector arm of the EGFR pathway is specifically
affected by the sy262 mutation. Rescue of the EGFR (null)-
induced lethality and defective vulval induction was weak but
statistically significant. Together, these data indicate that the
G322R change only weakly increases the basal activity of
SOS-1. However, since SOS-1 G322R has strong rescuing ac-
tivity in the presence of nonnull mutations in the EGFR path-
way (which allows low levels of signaling) (Table 1), we infer
TABLE 3. The sy262 mutation is strongly dependent on upstream signaling by EGF
Genotypea Gonadb VulvalInductionc % Muv
d % Vule nf P valueg
Wild type  3.00 0 0 24
Wild type  0.00 0 100 14
let-23(rf); sy262  3.80 68 0 22
let-23(rf); sy262  0.00 0 100 19
let-23(rf); let-60(gf)/  4.58 100 0 20
let-23(rf); let-60(gf)  5.38 100 0 20
let-23(rf); let-60(gf)  1.17 12 88 16 0.01 to wild type
gonad ablated
a let-23(rf)  let-23(sy1), let-60(gf)  let-60(n1046gf), and sy262 was linked to him-5(e1490).
b The gonadal primordium, which gives rise to the EGF-producing anchor cell, is either present () or removed by laser ablation ().
c Average number of vulval progenitor cells adopting vulval fates. Wild type is three. The maximum is six.
d The percentage of animals that have more than three vulval progenitor cells adopting vulval fates.
e The percentage of animals that have fewer than three vulval progenitor cells adopting vulval fates.
f n, number of animals examined.
g Statistical significance of the vulval induction value as determined by a two-tailed Student’s t test.
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that G322R acts by increasing the responsiveness of SOS-1 to
upstream signaling.
The SOS-1 Dbl domain is a critical developmental inhibitor
of Ras signaling. Our data suggest that during C. elegans vulval
development, a major function of the Dbl domain is to prevent
excessive Ras activation by the CDC25 Ras GEF domain. To
determine the importance of this negative regulatory mecha-
nism relative to that of established trans-acting inhibitors of the
EGFR-Ras-MAPK pathway, we compared sy262 suppression
of a reduction-of-function mutation in let-23 (EGFR) to that
conferred by loss-of-function mutations in sli-1 (c-Cbl) (96),
gap-1 (RasGAP) (37), and lip-1 (MAPK phosphatase) (7). We
found that the sy262 mutation was a better suppressor of the
let-23 (EGFR) mutation than a likely null mutation in lip-1
(MAPK phosphatase) and equivalent in strength to null mu-
tations in either sli-1 (c-Cbl) or gap-1 (RasGAP) (Table 5). To
further determine the importance of the Dbl domain for inhi-
bition of the EGFR-Ras-MAPK signaling pathway, we con-
structed a double mutant harboring the sy262 mutation and a
null mutation in gap-1 (RasGAP). Together, these mutations
should increase GTP loading on Ras while reducing its GTPase
activity. Individually, these single mutations do not disrupt vulval
development. However, 25% of double-mutant animals displayed
excessive vulval differentiation (Table 5). Thus, the SOS-1 Dbl
domain helps provide a critical balance between the opposing
GEF and GAP activities that regulate Ras.
A mutation equivalent to sy262 G322R activates hSOS1. To
further study the molecular mechanism of action of the sy262
G322R mutation and to determine whether hSOS1 might be
regulated in a similar manner, we sought to introduce the
equivalent activating mutation into the hSOS1 cDNA. We
used the solved X-ray crystal structure of the Dbl-PH-REM-
CDC25 domains of hSOS1 and SWISS-MODEL modeling
software (36, 67, 79) to generate a structural model of C.
elegans SOS-1 (Fig. 3). In this model, G322 lies in the H3 helix
of the Dbl domain. The equivalent residue in hSOS1 appears
TABLE 4. The sy262 mutation displays very weak activity in the absence of functional EGFRs
Genotypea
% Suppression of let-
23(null)-induced
lethalityb
P valuec
% Suppression of let-
23(null)-induced
sterilityd
Vulval inductionf % Muvh % Vuli nj P valuek
let-23(null) 0 (1,091) NAe NAg NAg NAg NAg
let-23(null); sy262 6 (1,372) 0.001 0 (16) 0.98 0 91 11 0.013
let-23(null); let-60(gf) 100 (324) 0.0001 0 (44) 5.73 100 0 11 0.00001
a The complete genotype of let-23(null) was rol-6(e187) let-23(sy16); let-60(gf)  let-60(n1046gf); sy262 was linked to him-5(e1490).
b Suppression of lethality was calculated from strains that were homozygous for the sy262 or let-60 mutation but heterozygous for the rol-6(e187) let-23(sy16)
chromosome. In the absence of suppression, rolling adults never appear. In the presence of complete suppression, 25% of total descendants from the rol-6(e187)
let-23(sy16) heterozygous parents would be rolling; 100% suppression is normalized to the generation of 25% rollers relative to total progeny. The number in
parentheses refers to the total number of progeny examined from rol-6(e187) let-23(sy16) heterozygous parents.
c The statistical significance of the observed frequency of viable animals was determined by comparison with let-23(null) animals alone and using a chi square test.
d Animals suppressed for let-23(null)-induced lethality were picked as L4 larvae and examined for progeny 4 days later. The number in parentheses refers to the total
number of animals examined.
e NA, not applicable. Due to the 100% penetrant lethality conferred by the homozygous let-23(null) mutation, these animals could not be examined for sterility; 100%
sterility, however, is inferred from reduction-of-function mutations in lin-3 and LET-23 structure-function studies.
f Average number of vulval progenitor cells adopting vulval fates. Wild type is three. The maximum is six.
g NA, not applicable. Due to the 100% penetrant lethality conferred by the homozygous let-23(null) mutation, these animals could not be examined for vulval
induction. However, based on certain combinations of let-23 alleles, it could be inferred that the vulval induction of these animals would be 0.00 and that 0% of the
animals would be Muv.
h Percentage of animals with more than three vulval progenitor cells adopting vulval fates.
i Percentage of animals with fewer than three vulval progenitor cells adopting vulval fates.
j n, number of animals examined for vulval induction.
k The statistical significance of the vulval induction value was determined by comparison with gonad-ablated wild-type animals and use of a two-tailed Student’s t test.
TABLE 5. Magnitude of inhibition of the SOS-1 Dbl domain, c-Cbl, RasGAP, and MAPK phosphatase on the EGFR pathway
Genotypea Vulval inductionb % Muvc % Vuld ne P valuef
let-23(rf) 0.23 0 100 20
sli-1(null) 3.00 0 0 24
let-23(rf); sli-1(null) 3.57 60 17 30 0.00001 to let-23(rf)
gap-1(null) 3.00 0 0 36
let-23(rf); gap-1(null) 3.74 71 0 21 0.00001 to let-23(rf)
lip-1(null) 3.00 0 0 20
let-23(rf); lip-1(null) 2.10 0 52 21 0.00001 to let-23(rf)
sy262 3.00 0 0 24
let-23(rf); sy262 3.80 68 0 22 0.34 to let-23(rf); sli-1(null), 0.80 to let-23(rf); gap-1(null),
and 0.00001 to let-23(rf); lip-1(null)
sy262; gap-1(null) 3.26 26 0 35 0.004 to gap-1(null) and sy262
a let-23(rf)  let-23(sy1), and sli-1(null)  sli-1(sy143). The complete genotype of gap-1(null) is gap-1(n1691) unc-2(e55). lip-1(null)  lip-1(zh15); sy262 was linked
to him-5(e1490).
b Average number of vulval progenitor cells adopting vulval fates. Wild type is three. The maximum is six.
c Percentage of animals with more than three vulval progenitor cells adopting vulval fates.
d Percentage of animals with fewer than three vulval progenitor cells adopting vulval fates.
e n, number of animals examined.
f The statistical significance for the vulval induction value was determine using a two-tailed Student’s t test.
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FIG. 3. Conservation of the Dbl and REM domains between human and C. elegans SOS proteins. (A) Crystal structure of the Dbl-PH-REM-
CDC25 domains from hSOS1 at 3.62 Å (84). The yellow residues (L687, R688, and W729) indicate amino acids in the REM domain that interact
with Ras-GTP and are important for Ras-GTP-dependent allosteric stimulation of CDC25 activity. The green residues in the Dbl helix H2b (E268
and M269) and loop (D271) contribute to autoinhibition of the REM domain. Substitution mutations converting all three green amino acids to
alanines result in a protein that is hypersensitive to allosteric activation (84). The blue residues (L259, H262, I263, and V267) in helix H2b point
toward the surface of helix H3. C282 in helix H3 is in the position analogous to that of the sy262 G322R mutation in the C. elegans Dbl domain.
SWISS-MODEL modeling suggested that a C282R change might not be compatible with the normal geometry of the blue residues in helix H2b.
(B) SWISS-MODEL of the C. elegans Dbl-PH-REM-CDC25 domains from SOS-1. Note the conservation of the yellow residues (L764, R765, and
F812) in the REM domain for allosteric stimulation of CDC25 activity by Ras-GTP, conservation of the green residues (E312, L313, and D315)
in the Dbl domain for potential autoinhibition of the REM domain, and conservation of the blue bulky/hydrophobic residues (I303, T306, L307,
and I311) that face the surface of Dbl helix H3. SWISS-MODEL modeling suggests that the G322R change in helix H3 may not be compatible
with the predicted geometry of the blue residues in helix H2b. (C) BLAST alignments of relevant portions of the REM and Dbl domains between
human and C. elegans SOS proteins. The red amino acids in the REM domain are important for binding Ras-GTP. The blue bar indicates the
position of Dbl helix H2b (predicted in C. elegans), and the green bar indicates the position of Dbl helix H3 (predicted in C. elegans). The green
amino acid is the locations of the sy262 mutation. Plusses indicate conservative amino acid changes between the human and C. elegans proteins.
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to be C282, which is not disulfide bonded in the crystal struc-
ture. In both the human and C. elegans proteins, these residues
appear to be essential to accommodate the bulky side chains
from residues in the nearby H2b helix. It is thus conceivable
that the G322R change in C. elegans SOS-1 is incompatible
with the normal positioning of the H2b helix and that a similar
effect might be obtained by a C282R change in hSOS1.
Since C. elegans SOS-1 G322R predominantly acts by en-
hancing the signal-dependent output of an EGFR-Ras-MAPK
pathway, we examined the ability of transfected hSOS1 C282R
to enhance EGF-dependent MAPK activation in serum-
starved mammalian cell lines (Fig. 4). In NIH 3T3 cells, com-
pared to transfection of wild-type hSOS1, hSOS1 C282R was
able to enhance the amplitude and duration of MAPK activa-
tion (Fig. 4A). Although from experiment to experiment there
was variability in the extent to which MAPK was activated, we
were able to establish statistical significance (P  0.05) for
differences in MAPK activation at 15 and 60 min following
EGF stimulation (Fig. 4B). On average, the differences be-
tween the activities of the wild-type and mutant proteins were
two- to threefold. To further validate this result, we also per-
formed the same experiment in HEK 293 EBNA cells. Once
again, we found that compared to wild-type hSOS1, hSOS1
C282R was more potent at promoting EGF-dependent MAPK
activation (Fig. 4C). Compared to NIH 3T3 cells, in HEK 293
EBNA cells, the time points at which differences in activity
were manifested were more variable. Thus, it was harder to
establish statistical significance. Nevertheless, in every experi-
ment we found that at some time point, hSOS1 C282R dis-
played two- to fourfold more activity than wild-type hSOS1. In
conjunction with our genetic data, these data suggest that the
G322R change in C. elegans SOS-1, as well as the equivalent
C282R change in hSOS1, does indeed enhance EGF-depen-
dent MAPK activation. Thus, it is likely that the Dbl domain
normally acts to dampen the amount of EGF-dependent
MAPK activation and that the structural mechanism by which
this is accomplished is conserved across species.
DISCUSSION
Although SOS is an evolutionarily conserved critical regu-
lator of RTK-Ras-MAPK signaling, the key mechanisms that
regulate its biologic activity in vivo are not well-defined. It was
initially thought that RTK-dependent translocation of SOS to
its substrate Ras at the plasma membrane was the key mech-
anism that controlled Ras-MAPK activation (3). However, sev-
FIG. 4. A C282R mutation in hSOS1 is functionally equivalent to
the sos-1(sy262) G322R mutation in C. elegans SOS-1. (A) hSOS1
C282R promotes EGF-dependent MAPK activation in NIH 3T3 cells.
The cells were transfected with 2 to 4 g of FLAG-tagged hSOS1
expression vector and 4 g of HA-ERK1 (MAPK) expression vector.
After serum starvation and stimulation with EGF for the indicated
times, whole-cell lysates were prepared and analyzed by Western blot-
ting with the indicated antibodies. Phosphorylated and total trans-
fected MAPKs were distinguished from endogenous MAPK by a mo-
bility shift caused by the HA tag on the MAPK in the transfection
construct. Representative blots from two independent experiments are
shown. Activation (n-fold) was calculated by dividing the 	-phospho-
MAPK signal by the 	-total-MAPK signal and then adjusting the
values to that observed with wild-type hSOS1 at the zero time point.
(B) Mean results from four independent experiments in NIH 3T3 cells,
where the wild-type and mutant hSOS1 constructs were similarly ex-
pressed and the control wild-type hSOS1 construct caused similar
levels of MAPK activation between experiments. Normalized activa-
tion (n-fold) is as described for panel A, except that 	-phospho-
MAPK/	-total MAPK ratios were also adjusted for slight differences in
transfected hSOS1 expression. Statistical significance was assessed us-
ing a one-tailed Student’s t test. (C) hSOS1 C282R promotes EGF-
dependent MAPK activation in HEK 293 EBNA cells. The cells were
transfected with 2 to 4 g of FLAG-tagged hSOS1 expression vector
and 2.5 g of HA-ERK1 (MAPK) expression vector. After serum
starvation and stimulation with EGF for the indicated times, whole-cell
lysates were prepared and analyzed by Western blotting as described
for panel A. Representative blots from two independent experiments
are shown.
3702 MODZELEWSKA ET AL. MOL. CELL. BIOL.
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on July 28, 2007 
m
cb.asm
.org
D
ow
nloaded from
 
eral lines of evidence have suggested that control of SOS
activity in the Ras-MAPK pathway might be more complex.
First, in Drosophila melanogaster, in the absence of the
SEVENLESS RTK or Grb2, SOS still localizes to the plasma
membrane, yet Ras signaling is impaired (9, 49). Second, SOS
structure-function studies have identified autoinhibitory effects
of the N and C termini (20, 51, 93) and have suggested that
growth factor signaling might be required to relieve these or
other inhibitory mechanisms (14, 70). Third, although their
developmental significance is not yet clear, a number of mod-
ifications/protein-protein interactions have been described that
can alter the activities of either the Rac or Ras GEF domains
of SOS. For example, Rac GEF activity of the Dbl domain is
autoinhibited through interactions with the PH domain and is
relieved by PI3 kinase signaling (23, 65, 83). Rac GEF activity
also can be stimulated by protein interactions with Eps8 and
Abi-1 (80, 81), as well as tyrosine phosphorylation by Abl (82).
Finally, Ras GEF activity is allosterically stimulated through a
positive feedback mechanism involving the binding of Ras-
GTP to the REM domain (58). A two-pronged mechanism for
controlling SOS activity, involving both translocation and sig-
naling-dependent modifications/protein-protein interactions,
would be consistent with emerging data regarding regulation of
other GEFs. In a basal state, the Rho family GEF Vav is
autoinhibited by the insertion of Tyr 174 from the N-terminal
acidic region into the Dbl domain active site (1). This autoin-
hibition can be further compounded by PIP2-dependent inter-
actions between the PH and Dbl domains (39). Signaling lead-
ing to phosphorylation of Tyr 174 and the generation of PIP3
disrupts both inhibitory mechanisms and increases Vav cata-
lytic activity (1, 22, 25, 38, 39). Similarly, the catalytic activity of
the Ral GEF Ral-GDS is inhibited via its N-terminal REM
domain (77). In this case, signaling resulting in PI3 kinase
activation promotes the association of another protein, PDK1,
with the REM domain and relieves this inhibition (91).
We have discovered a novel gain-of-function mutation in the
sos-1 gene that increases EGFR-Ras-MAPK pathway output
during C. elegans vulval development. The localization of this
mutation to the Dbl domain (G322R) implies that this domain
normally confers some type of inhibition on EGFR signaling.
SOS-1 G322R restores signaling to animals defective in EGF
processing and EGFR localization and overcomes inhibition
by one class of dominant-negative Ras protein (Table 1).
Given that SOS possesses both Rac and Ras GEF activities
and that the sy262 mutation lies within the Rac GEF Dbl
domain, it is possible that the mutation acts through one or
both of the GTPases. We favor a model in which the predom-
inant effect of the G322R change is on Ras activation. First,
SOS-1 G322R does not appear to act through any of the
canonical mechanisms implicated in Rac-dependent MAPK
activation. Current models involve activation of Pak by Rac
and subsequent phosphorylation of either Raf or Mek. Pak can
directly phosphorylate Raf on S338 (52), which is an activating
modification, or it can phosphorylate Mek and enhance its
binding to Raf and MAPK (27, 33, 97). C. elegans Raf has an
aspartate residue at the analogous position of S338. Thus, the
importance of an acidic charge is conserved, but not the use of
protein phosphorylation at this position. Furthermore, our ge-
netic epistasis results indicated that SOS-1 G322R acts up-
stream of Mek and Raf and possibly Ras activation (Table 1).
Second, further genetic analysis indicated that SOS-1 G322R is
more sensitive to reductions in Ras than in Rac levels (Table
2). Homozygous null and severe reduction-of-function muta-
tions in two of the three C. elegans Rac genes (rac-2 and
ced-10) had no effect on SOS-1 G322R activity, while a null
mutation in the third Rac gene, mig-2, had only a partial effect.
In fact, even a homozygous null mutation in mig-2 coupled with
RNAi-induced reductions in the other Rac genes still allowed
SOS-1 G322R to have 69% of its normal activity. In contrast,
animals heterozygous for a strong reduction-of-function muta-
tion in Ras retained only 29% of SOS-1 G322R activity. This
result is even more striking considering that, by itself, the
heterozygous state of the Ras(rf) mutation does not impair any
known Ras-dependent pathway, while the homozygous state of
the mig-2(null) mutation disrupts Q-cell descendant migration
in 85% of animals (98). Finally, by itself, a null mutation in
mig-2 (Rac) has no effect on vulval development (Table 2),
while reduction-of-function mutations in Ras severely impair
vulval development; furthermore, an activated Ras mutant al-
most fully restores wild-type vulval development to sos-1(null)
animals (5, 15, 40). These data suggest that Ras is the key
GTPase normally downstream of SOS-1 during vulval devel-
opment. However, it remains possible that MIG-2 (Rac) par-
tially contributes to the effect of SOS-1 G322R through a novel
mechanism or that it functions through an independent path-
way parallel to SOS-1 G322R. For example, the Rho family
GEF UNC-73 (Trio) acts on MIG-2 (Rac) to regulate vulval
cell divisions and cell migrations (53, 85). Furthermore, MIG-2
(Rac) is expressed in cell types other than the VPCs, including
neurons (98), which can indirectly regulate vulval development
(60).
The Dbl domain could control Ras-MAPK signaling through
several mechanisms. Regulatory proteins could constitutively
bind to the Dbl domain and sterically interfere with CDC25
Ras GEF activity. Alternatively, the Dbl domain could inter-
fere with CDC25 activity through an autoinhibitory mecha-
nism. trans-acting inhibitors of CDC25 function that bind di-
rectly to SOS have not yet been identified. On the other hand,
an autoinhibitory function of the Dbl domain on CDC25 ac-
tivity has been described (84). X-ray crystallographic and bio-
chemical studies indicate that activated Ras (Ras-GTP) can
bind to the SOS REM domain and allosterically stimulate the
Ras GEF activity of the CDC25 domain (31, 58). However, the
SOS crystal structure indicates that accessibility of Ras-GTP to
the allosteric site is restricted by the H2b helix of the Dbl
domain (84) (Fig. 3A). Specific substitution mutations in the
H2b helix at the interface with the REM domain can relieve
some of this inhibition (84). A triple mutant of E268A/M269A/
D271A has little effect on basal CDC25 activity but increases
the sensitivity to Ras-GTP activation by 20-fold. We used a
BLAST alignment between the human and C. elegans SOS
proteins, along with SWISS-MODEL, to generate a three-
dimensional model of C. elegans SOS-1 (Fig. 3B and C). In this
model, it appears that the key structural determinants for au-
toinhibition by the Dbl domain and allosteric stimulation by
Ras-GTP are conserved between the two proteins. Our sy262
G322R mutation maps to the H3 helix of the Dbl domain,
which lies near the H2b inhibitory helix. In the crystal structure
of hSOS1 and our C. elegans SOS-1 model, multiple hydropho-
bic/bulky side chains in H2b face the surface of H3 (Fig. 3).
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These side chains are effectively accommodated by G322 and
C282 in the worm and human proteins, respectively. The
G322R change may prevent H2b from acquiring the correct
geometry necessary for blocking the allosteric Ras-GTP site in
the REM domain. In fact, consistent with this model, we find
that a C282R change in hSOS1 also generates an activated
mutant with properties similar to those of the C. elegans SOS-1
G322R. hSOS1 C282R does not display an obvious increase in
basal activity but can enhance EGF-dependent MAPK activa-
tion (Fig. 4). Thus, if our model is correct, the sy262 mutation
would provide strong support for the in vivo existence of the
allosteric stimulatory/autoinhibitory functions of the REM and
Dbl domains and would demonstrate their critical roles in
regulating EGFR-Ras-MAPK signaling during development.
A central question, however, remains regarding the role of
EGFR signaling in regulating SOS activity and Ras activation.
Although the sy262 G322R mutation weakly increases basal
activity (Table 4), mutant SOS-1 is still largely dependent on
EGFR signaling for pathway activity (Table 3). This depen-
dence could reflect the requirement for phosphorylated recep-
tors to translocate Grb2-SOS-1 complexes to Ras at the plasma
membrane. However, it is also tempting to speculate that
SOS-1 itself is modified by activated receptors and that this
modification is necessary for its full activity. SOS is phosphor-
ylated immediately following EGFR activation (76), and it has
recently been reported that allosteric stimulation of SOS by
Ras-GTP requires growth factor signaling, unless SOS is trun-
cated at the N and C termini (12). One interpretation of these
results is that receptor signaling is necessary to relieve autoin-
hibition by the Dbl domain and to allow positive feedback by
Ras-GTP. Such feedback may ultimately be necessary to sus-
tain sufficient levels of MAPK activity to drive specific cell fate
changes, as seen during vulval development. Thus, the G322R
change may bypass the requirement for receptor signaling to
allow positive feedback by Ras-GTP but not bypass the re-
quirement for activated receptors to translocate SOS to Ras at
the plasma membrane. Alternatively, the G322R change may
only partially increase the accessibility of the allosteric site to
Ras-GTP. Thus, a subthreshold amount of EGFR signaling
might still be required to cooperate with the G322R change to
fully allow positive feedback regulation by Ras-GTP.
One unexpected result is that the sos-1(sy262) mutation can
suppress one class of dominant-negative Ras mutation, but not
another (Table 1). SOS-1 G322R can overcome inhibition con-
ferred by a heterozygous Ras S89F mutation, but not a het-
erozygous Ras G10R or G15D mutation. SOS-1 G322R also
can weakly improve signaling in Ras S89F homozygotes. Ras
S89F homozygotes are normally inviable. However, we could
recover hermaphrodites homozygous for both the Ras S89F
and SOS-1 G322R mutations, and starting with 25 hermaph-
rodites, we could maintain this population for an additional 2
generations before they died. Thus, consistent with an overex-
pression analysis of the different classes of dominant-negative
Ras mutants (42), we found that the S89F mutant retained
some biologic activity and could be regulated by SOS-1.
All nine of the dominant-negative Ras mutations isolated in
C. elegans affect residues conserved in human Ras proteins
(42). The G10R and G15D changes occur in the phosphate-
binding P loop. P-loop mutations, such as those affecting G15,
severely impair nucleotide and effector binding while increas-
ing the affinity for GEFs (18, 46, 63, 68). This class of domi-
nant-negative mutant likely acts by sequestering a limiting
amount of GEF into a nonproductive signaling complex. S89 is
in helix 3 and does not appear to make contact with nucleo-
tides or SOS (10, 66), although an S89F change may affect the
positioning of the P loop (Fig. 5). S89F may be a weaker class
of dominant-negative mutant due to a weaker perturbation in
nucleotide binding and a weaker increased interaction with
SOS. As tempting as this model is, it cannot be entirely com-
plete or correct. sur-5 reduction-of-function mutations were
isolated as suppressors of a dominant-negative K16N P-loop
mutation in Ras (35). sur-5 mutations also suppress other P-
loop mutations, but not an S89F mutation. If Ras S89F acted
as a dominant negative through the same mechanism as the
P-loop mutants, it should also be suppressible by loss of
SUR-5, since it is a weaker mutant. These results have led to
the proposal that P-loop mutants and the S89F mutant act
through different mechanisms (35). One possibility is that
there is a second Ras GEF that is selectively inhibited by
SUR-5 and, under some conditions, may be able to feed into
the Ras pathway (35) (Fig. 6). This notion is supported by
evidence that an activated G13E Ras mutant still exhibits
EGF-dependent activity in the complete absence of SOS-1 and
that the C. elegans genome predicts the existence of at least five
other Ras GEFs (15). In one model (Fig. 6, model 1), strong
inactivation of SOS-1 by dominant-negative Ras P-loop mu-
tants allows the second Ras GEF to be wired into the Ras
pathway. Thus, this class of mutation would be suppressible by
a sur-5 mutation, but not by the sos-1(sy262) mutation. In
contrast, an S89F Ras mutant may only partially inactivate
SOS-1 and not allow the second Ras GEF to wire into the Ras
pathway. Thus, this class of mutation would be suppressible by
the sos-1(sy262) mutation, but not by a sur-5 mutation. Alter-
natively (Fig. 6, model 2), the second Ras GEF may be con-
FIG. 5. Crystal structure of human H-Ras complexed with the GTP
analogue GppNp (66). The phosphate-binding P loop is highlighted in
green. The positions of residues that when mutated give rise to two
classes of dominant-negative Ras proteins are indicated (G15, red;
S89, yellow).
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stitutively wired into the Ras pathway but selectively targeted
by the S89F Ras mutant. In this case, the S89F mutation would
still be suppressible by the sos-1(sy262) mutation, but not by a
sur-5 mutation. Selective effects of different dominant-negative
Ras mutants on different GEFs may be a general property of
Ras proteins. In Saccharomyces cerevisiae, a P-loop dominant-
negative RAS2 mutant acts exclusively through a CDC25-de-
pendent mechanism, while a D64Y (D57Y in human H-Ras)
mutant can act independently of CDC25 (46).
Although the requirement for the SOS CDC25 domain in
regulating RTK-mediated Ras signaling in vivo is well estab-
lished (9, 15, 69, 75, 92), it is less clear to what extent and how
the Dbl domain might regulate development. In fact, the first
genetic role for the SOS Dbl domain has just recently been
reported. In Drosophila melanogaster, Rac GEF activity from
the Dbl domain, but not Ras GEF activity from the CDC25
domain, is necessary for ROBO-mediated axon guidance (32,
95). Our genetic data indicate that the SOS Dbl domain per-
forms an additional critical function during development. It
inhibits RTK-Ras-MAPK signaling. This form of inhibition is
extremely significant. It is of the same magnitude as estab-
lished trans-acting inhibitors, such as c-Cbl, RasGAP, and
MAPK phosphatase (Table 5). Furthermore, although the
worms appeared to be able to cope with the single loss of
Dbl-conferred inhibition (through the sy262 mutation), they
were on the threshold of having abnormal development. In the
further absence of RasGAP, which would also decrease Ras
GTPase activity, vulval development was no longer normal, as
25% of the double-mutant animals displayed ectopic vulvae
(Table 5). These results highlight the developmental impor-
tance of the Dbl domain in properly balancing Ras GEF and
GAP activities in order to achieve proper signaling intensity.
The identification of a single missense mutation in the
SOS-1 Dbl domain that can significantly alter development in
sensitized backgrounds suggests that functionally similar mu-
tations in hSOS1 may contribute to Ras-dependent malignan-
cies. In fact, we found that a C282R mutation in hSOS1, which
is analogous to the activating G322R change in C. elegans
SOS1, also created a gain-of-function protein (Fig. 4). More-
over, while this work was in revision, it was reported that
activating mutations in hSOS1 occur in patients with Noonan
syndrome (73, 90). Approximately 50% of Noonan patients
carry activating mutations in PTPN11, a positive regulator of
Ras signaling (88), and a few other patients carry novel, weakly
activating mutations in K-Ras (78). Aside from the develop-
mental abnormalities associated with Noonan syndrome, pa-
tients are predisposed to develop juvenile leukemias and my-
eloproliferative disorders commonly associated with mutations
in the Ras pathway (55). Noonan-associated SOS1 mutations
occur throughout the gene, affecting the histone fold region,
the Dbl domain, the PH domain, the REM domain, the
CDC25 domain, and the helical linker between the PH and
REM domains (73, 90). Our work agrees with the general
conclusions of these studies, namely, that disruption of auto-
inhibition on the allosteric site promotes Ras activation in vivo.
However, not all of the human mutations may act equivalently.
Some mutations affecting the Dbl domain, the CDC25 domain,
and the helical linker between the PH and REM domains
enhance EGF-dependent Ras and MAPK activation, which is
consistent with our genetic and biochemical studies with the
G322R and C282R mutations (73). Interestingly, one of these
mutations, M269R, lies in the H2b helix of the Dbl domain,
which directly interacts with the Ras-GTP allosteric site (84).
In vitro studies predicted that a mutation at M269 would dis-
rupt this interaction and enhance Ras and MAPK activation in
vivo (84). In contrast, a human W729L mutation in the REM
domain, which directly affects a residue that mediates binding
of Ras-GTP at the allosteric site, appears to act by increasing
basal activity toward Ras while having little effect on MAPK
activation (90). If the general model from all of these studies is
correct, our data provide direct support for the causal link
between the human mutations in SOS1 and the associated
developmental syndrome. The contributions of activating mu-
tations in the Ras pathway to human cancer have long been
appreciated (11). However, the strong activated nature of the
classic G12 mutations did not overtly predict the potential
contributions of weaker mutations that more subtly alter Ras
signaling intensity to cancer and developmental syndromes (6,
24, 26, 64, 74, 78, 89). Our work and the recent discoveries of
novel classes of activating mutations in components of the Ras
pathway in human disease highlight the complexity with which
perturbations in a single signaling pathway can lead to diverse
types of human disease.
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FIG. 6. Models for Ras GEF regulation by dominant-negative Ras
mutants in C. elegans VPCs. A second Ras GEF (RasGEF2) functions
in parallel to SOS. It may be constitutively wired into the Ras pathway,
or it may feed in only when SOS is inactivated. RasGEF2 is selectively
inhibited by SUR-5. P-loop dominant-negative Ras mutants, such as
G15D, strongly inactivate SOS. In model 1, inactivation of SOS by
P-loop mutants permits RasGEF2 to function in the Ras pathway.
Further inactivation of SUR-5 allows RasGEF2 to promote even more
Ras activation. S89F dominant-negative Ras mutants only partially
inactivate SOS and fail to allow RasGEF2 to feed into the Ras path-
way. Therefore, loss of SUR-5 in an S89F mutant background does not
enhance Ras activation. In model 2, RasGEF2 is constitutively wired
into the Ras pathway, and S89F dominant-negative Ras mutants se-
lectively inactivate RasGEF2. Thus, in an S89F background, loss of
SUR-5 still fails to promote Ras activation.
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